Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Metabolic · FDA Approved

Tirzepatide (Mounjaro/Zepbound)

FDA-approved

Start your consultation
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways, and in head-to-head trials produced greater HbA1c lowering and weight loss than the selective GLP-1 RA semaglutide in type 2 diabetes (PMID 34170647).

In adults with obesity without diabetes, it also produced greater weight and waist reduction than semaglutide (PMID 40353578).

02 · Research summary & key findings

SURMOUNT-1 showed mean body weight reductions of 15.0% to 20.9% at 72 weeks across doses versus 3.1% with placebo (PMID 35658024). SURPASS-2 demonstrated superior HbA1c reduction vs. semaglutide (PMID 34170647), and SURMOUNT-5 showed 20.2% vs. 13.7% weight loss vs. semaglutide in obesity (PMID 40353578). FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023).

03 · Regulatory status

Tirzepatide (Mounjaro/Zepbound) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

04 · Administration routes

  • Subcutaneous injection (weekly)

References

  1. [1]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes N Engl J Med, 2021. PMID 34170647
  2. [2]Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med, 2022. PMID 35658024
  3. [3]Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med, 2025. PMID 40353578

Primary literature

Related peptides in Metabolic

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.